The TAT-9C peptide, which disrupts the association between GluN2B and PSD95, was reported to be safe and efficient for ischemic stroke in a phase-2 clinical trial (Hill et al., 2012; Wu and Tymianski, 2018). The gene discussed is DLG4; the disease is ischemic stroke.